Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Hypersensitivity | 3 | 2026 | 90 | 1.800 |
Why?
|
| Anti-Bacterial Agents | 6 | 2026 | 1925 | 1.740 |
Why?
|
| Long-Term Care | 2 | 2026 | 118 | 1.670 |
Why?
|
| Penicillins | 3 | 2026 | 62 | 1.340 |
Why?
|
| Antimicrobial Stewardship | 1 | 2026 | 130 | 0.820 |
Why?
|
| Documentation | 1 | 2024 | 199 | 0.720 |
Why?
|
| Hypothermia | 1 | 2022 | 53 | 0.700 |
Why?
|
| Pseudomonas Infections | 1 | 2023 | 230 | 0.690 |
Why?
|
| Fever | 2 | 2022 | 319 | 0.670 |
Why?
|
| Public Health | 1 | 2026 | 574 | 0.670 |
Why?
|
| Candidemia | 1 | 2020 | 16 | 0.630 |
Why?
|
| Endocarditis | 1 | 2020 | 40 | 0.610 |
Why?
|
| Urinalysis | 1 | 2019 | 83 | 0.590 |
Why?
|
| Neutropenia | 1 | 2019 | 154 | 0.560 |
Why?
|
| Inpatients | 2 | 2022 | 553 | 0.540 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 210 | 0.500 |
Why?
|
| Cilastatin | 1 | 2016 | 2 | 0.480 |
Why?
|
| Imipenem | 1 | 2016 | 16 | 0.470 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2016 | 27 | 0.470 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2016 | 44 | 0.460 |
Why?
|
| Cryptococcosis | 1 | 2016 | 31 | 0.450 |
Why?
|
| Massachusetts | 2 | 2026 | 180 | 0.430 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 534 | 0.400 |
Why?
|
| Influenza, Human | 1 | 2018 | 624 | 0.370 |
Why?
|
| Hospitalization | 1 | 2019 | 2460 | 0.290 |
Why?
|
| Incidence | 3 | 2020 | 2933 | 0.270 |
Why?
|
| Middle Aged | 9 | 2026 | 36302 | 0.240 |
Why?
|
| Fluoroquinolones | 1 | 2026 | 44 | 0.240 |
Why?
|
| Benchmarking | 1 | 2026 | 191 | 0.220 |
Why?
|
| Humans | 13 | 2026 | 145763 | 0.200 |
Why?
|
| Cephalosporins | 1 | 2023 | 45 | 0.200 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2023 | 77 | 0.190 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 5922 | 0.190 |
Why?
|
| Aged | 6 | 2026 | 26215 | 0.190 |
Why?
|
| Blood Culture | 1 | 2022 | 27 | 0.180 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2023 | 365 | 0.180 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 6085 | 0.180 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2022 | 95 | 0.180 |
Why?
|
| Retrospective Studies | 4 | 2022 | 17325 | 0.170 |
Why?
|
| Female | 9 | 2026 | 79035 | 0.170 |
Why?
|
| Interleukin-6 | 1 | 2024 | 779 | 0.160 |
Why?
|
| Bacteriuria | 1 | 2019 | 12 | 0.150 |
Why?
|
| Male | 8 | 2026 | 73003 | 0.150 |
Why?
|
| Infusions, Parenteral | 1 | 2019 | 48 | 0.150 |
Why?
|
| Adult | 6 | 2026 | 40872 | 0.140 |
Why?
|
| Missouri | 1 | 2018 | 66 | 0.140 |
Why?
|
| Hospitals, Teaching | 1 | 2018 | 121 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 428 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 992 | 0.140 |
Why?
|
| Mortality | 1 | 2020 | 380 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2025 | 1202 | 0.130 |
Why?
|
| Prevalence | 1 | 2024 | 2874 | 0.130 |
Why?
|
| Cross Infection | 1 | 2019 | 260 | 0.120 |
Why?
|
| Immunocompetence | 1 | 2016 | 46 | 0.120 |
Why?
|
| Cryptococcus neoformans | 1 | 2016 | 21 | 0.120 |
Why?
|
| Outpatients | 1 | 2019 | 447 | 0.110 |
Why?
|
| Risk Factors | 2 | 2020 | 10917 | 0.110 |
Why?
|
| Drug Combinations | 1 | 2016 | 396 | 0.110 |
Why?
|
| Comorbidity | 1 | 2019 | 1662 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 484 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 8346 | 0.090 |
Why?
|
| Prognosis | 1 | 2020 | 4329 | 0.080 |
Why?
|
| United States | 1 | 2025 | 16123 | 0.070 |
Why?
|
| Boston | 1 | 2026 | 93 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2024 | 11793 | 0.060 |
Why?
|
| Focus Groups | 1 | 2026 | 572 | 0.050 |
Why?
|
| Young Adult | 1 | 2018 | 14251 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2024 | 2064 | 0.040 |
Why?
|
| Adolescent | 1 | 2018 | 22573 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2026 | 1683 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1505 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 2933 | 0.030 |
Why?
|